{
    "nct_id": "NCT04809467",
    "official_title": "A Phase 1b/2a Basket Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Combination Therapy With the Anti CD19 Monoclonal Antibody Tafasitamab and the PI3Kδ Inhibitor Parsaclisib in Adult Participants With Relapsed/Refractory Non Hodgkin Lymphoma or Chronic Lymphocytic Leukemia",
    "inclusion_criteria": "* Histologically confirmed R/R B-cell malignancy: DLBCL (THRLBCL, EBV-positive DLBCL of the elderly, Grade 3b FL, HGBL with MYC and BCL2 and/or BCL6 rearrangements, transformed lymphoma); MCL ((with cyclin D1 overexpression or t(11;14); FL (Grade 1, 2, 3a); MZL (extranodal, nodal, splenic) ; CLL, or SLL\n* Willingness to undergo biopsy\n* At least 2 prior systemic treatment regimens, including prior treatment with an anti-CD20 antibody (all cohorts) or prior treatment with a BTK inhibitor (CLL/SLL)\n* Relapsed, progressive, or refractory NHL or CLL\n* For NHL/SLL: Radiographically measurable nodal or extranodal disease (all cohorts except CLL)\n* ECOG-PS 0 - 2\n* LVEF ≥ 50%\n* Adequate renal, hepatic, bone marrow function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Any other histological type of lymphoma\n* Primary or secondary CNS lymphoma\n* Anticancer and/or investigational therapy within the past 30 days or 5 half-lives\n* Allogeneic stem cell transplantation within the past 6 months, or ASCT within 3 months before C1D1\n* Previous treatment with CD19-targeted therapy or PI3K inhibitors\n* Clinically significant cardiac disease\n* Other malignancy within the past 3 years\n* Active graft-versus-host disease\n* Stroke or intracranial hemorrhage within the past 6 months\n* Chronic or current active infectious disease\n* Positive virus serology for HCV, HBV, HIV\n* Currently pregnant or breastfeeding",
    "miscellaneous_criteria": ""
}